An Open-Label Safety Extension Study to a Multicenter Study of Liposomal Amikacin for Inhalation (LAI) in Adult Patients with Nontuberculous Mycobacterial (NTM) Lung Infections caused by Mycobacterium avium complex (MAC) That are Refractory to Treatment
Phase of Trial: Phase III
Latest Information Update: 03 Jan 2018
At a glance
- Drugs Amikacin (Primary)
- Indications Mycobacterium avium complex infections; Respiratory tract infections
- Focus Adverse reactions
- Sponsors Insmed
- 03 Jan 2018 According to an Insmed media release, 163 patients have been enrolled as of December 2017.
- 03 Jan 2018 Interim results (n=124) presented in an Insmed media release.
- 30 Aug 2017 This trial has been completed in Spain.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History